CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients
NCT02575261
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
WITHDRAWN
Status
OTHER
Sponsor class
Conditions
EphA2 Positive Malignant Glioma
CAR-T Cell Immunotherapy
Interventions
BIOLOGICAL:
CAR-T cell immunotherapy
Sponsor
Fuda Cancer Hospital, Guangzhou